A Multicenter, Randomized, Double-blind, Parallel-group, Placebo-controlled Study of Fevipiprant Once Daily Plus Standard-of-care (SoC) for Assessment of the Efficacy in Reduction of Nasal Polyp Size in Patients With Nasal Polyposis and Concomitant Asthma.
Trial Snapshot
- Phase
- Phase 3
- Status
- Completed
- Sponsor
- Novartis Pharmaceuticals
- Enrollment
- 98
- Locations
- 1
- Primary Endpoint
- Change From Baseline in Nasal Polyp Score at Week 16
Study Overview
Brief Summary
A Phase 3b Proof-of-Concept study to evaluate the ability of fevipiprant 150 mg and 450 mg, compared with placebo, as add-on to nasal spray standard-of-care (SoC), in reducing endoscopic nasal polyp score in adult (≥ 18 years) patients with nasal polyposis and concomitant asthma.
Detailed Description
This was a Phase 3b, Proof-of-concept study with a randomized, multicenter, double-blind, placebo-controlled, parallel-group study design to determine the ability of fevipiprant plus standard of care (SoC) compared to placebo plus SoC to reduce the size of nasal polyps. The study enrolled adult male and female patients diagnosed with nasal polyposis with a nasal polyp score assessed by nasal endoscopy ≥ 4 at baseline with a minimum score of 2 in each nostril and a concomitant diagnosis of asthma. Patients who meet the inclusion/exclusion criteria were randomized in 1:1:1 ratio in either of the 3 arms fevipiprant 450 mg dose once daily (o.d.), fevipiprant 150 mg dose o.d. or placebo o.d. in addition to SoC (mometasone furoate spray).
The study included:
- a Screening period of 2 weeks to assess eligibility
- a Run-in period of 4 weeks where patients utilized mometasone furoate spray (200 μg once daily, administered as two 50 μg actuations into each nostril)
- a Treatment period of 16 weeks. Patients continued to use the mometasone furoate SoC throughout the treatment period.
- a Follow-up period of 2 weeks following the last dose of study drug to collect additional data for safety variables.
The purpose of this study was to evaluate the efficacy and safety of fevipiprant 150 mg and 450 mg compared to placebo in the reduction of nasal polyps size and the effect on symptoms, quality of life and smell via patient-reported outcomes in patients with nasal polyposis and concomitant asthma.
Study Design
- Study Type
- Interventional
- Allocation
- Randomized
- Intervention Model
- Parallel
- Primary Purpose
- Treatment
- Masking
- Double (Participant, Investigator)
Masking Description
Double blind, double dummy study design.
Eligibility Criteria
- Ages
- 18 Years to — (Adult, Older Adult)
- Sex
- All
- Accepts Healthy Volunteers
- No
Inclusion Criteria
- •Patients aged 18 years or more with a diagnosis of nasal polyps with Nasal polyp score >= 4 with minimum score of 2 in each nostril.
- •Concomitant diagnosis of asthma for a period of at least 6 months prior to screening.
- •Patients on stable asthma treatment of at least inhaled corticosteroids (any dose) alone for at least 6 months prior to screening or ICS for 6 months prior to screening with any required, inhaled medication (LABA, LAMA) added at least 6 weeks prior to screening.
Exclusion Criteria
- •Asthma exacerbation, within 6 weeks prior to screening, that required systemic corticosteroids, hospitalization or emergency room visit.
- •Chronic/maintenance use of oral corticosteroids (OCS) defined as any continuous use of OCS for a period of 1 month or more, within 1 year of screening
- •Use of biologics for asthma or any other indications, that has the potential to interfere/affect either asthma or nasal polyposis disease progression, within 6 months of screening.
- •Use of medication for sino-nasal symptoms (antibiotics with or without OCS) within 30 days of screening or during the run-in period.
- •Use of tetracycline or macrolide antibiotics specifically, within 8 weeks of screening.
- •History of nasal surgery modifying the structure of the nose such that assessment of the nasal polyp score is not possible.
- •Patients with baseline ACQ-5≥1.5
Arms & Interventions
Fevipiprant 150 mg
Fevipiprant (QAW039) 150 mg once daily orally
Intervention: Fevipiprant 150 mg (Drug)
Fevipiprant 450 mg
Fevipiprant (QAW039) 450 mg once daily orally
Intervention: Fevipiprant 450 mg (Drug)
Placebo
Placebo once daily orally
Intervention: Placebo (Drug)
Outcomes
Primary Outcomes
Change From Baseline in Nasal Polyp Score at Week 16
Time Frame: Baseline, Week 16
Nasal Polyp Score (NPS) is the sum of the right and left nostril scores, as evaluated by means of nasal endoscopy. Total score ranges from 0 to 8 (scored 0 \[no polyp\] to 4 \[large polyps\] for each nostril), with a lower score indicating smaller-sized polyps. Baseline NPS is defined as the last measurement performed on or before the date of randomization. A negative change from baseline in NPS is considered a favorable outcome.
Secondary Outcomes
- Change From Baseline in Nasal Congestion Score at Week 16(Baseline, Week 16)
- Change From Baseline in Quality of Life as Assessed by the SNOT-22 Questionnaire at Week 16(Baseline, Week 16)
- Change From Baseline in Sense of Smell as Assessed by the University of Pennsylvania Smell Identification Test (UPSIT) at Week 16(Baseline, Week 16)